Valuation: BioNTech SE

Market Cap 21.75B 24.36B 20.24B 18.41B 34.75B 2,357B 34.9B 244B 95.43B 1,202B 91.46B 89.46B 3,857B P/E 2026 *
-14.7x
P/E 2027 * -15.8x
Enterprise Value 10.66B 11.94B 9.92B 9.02B 17.04B 1,156B 17.11B 119B 46.78B 589B 44.84B 43.85B 1,891B EV / Sales 2026 *
5.97x
EV / Sales 2027 * 6.72x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+5.68%
Current month-2.55%
Current year-2.55%
3 years 81.95
Extreme 81.95
102.8
5 years 81.95
Extreme 81.95
335
10 years 11.5
Extreme 11.5
396.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 31/12/2017
Chief Executive Officer 61 01/06/2008
Director of Finance/CFO - 30/06/2025
Director TitleAgeSince
Chairman 56 01/06/2008
Director/Board Member 69 01/06/2008
Director/Board Member 65 31/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
+5.68%+0.70% - - 24.36B
-2.59%-5.70%+50.69%+79.01% 70.61B
+3.23%-10.67%+6.27%+53.48% 51.01B
+1.56%+1.17%+8.49%+32.39% 48.1B
+0.39%+0.65%+31.14%+27.04% 42.78B
+0.87%-8.17%+293.37%+643.87% 40.67B
+1.24%-1.01%+10.74%+94.55% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-1.30%-3.97%+47.53%+7.15% 28.16B
+5.32%+0.06%-5.00%-12.60% 24.36B
Average +1.24%-2.66%+50.21%+107.89% 41.84B
Weighted average by Cap. +0.82%-2.94%+51.74%+112.40%

Financials

2026 *2027 *
Net sales 1.79B 2B 1.66B 1.51B 2.86B 194B 2.87B 20.01B 7.84B 98.74B 7.51B 7.35B 317B 1.8B 2.01B 1.67B 1.52B 2.87B 195B 2.88B 20.11B 7.88B 99.25B 7.55B 7.39B 318B
Net income -1.43B -1.6B -1.33B -1.21B -2.28B -154B -2.29B -15.96B -6.25B -78.73B -5.99B -5.86B -253B -1.31B -1.47B -1.22B -1.11B -2.1B -142B -2.11B -14.7B -5.76B -72.55B -5.52B -5.4B -233B
Net Debt -11.09B -12.42B -10.32B -9.38B -17.72B -1,202B -17.79B -124B -48.65B -613B -46.63B -45.61B -1,966B -9.68B -10.84B -9B -8.19B -15.46B -1,049B -15.53B -108B -42.45B -535B -40.69B -39.8B -1,716B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change
09/10/26 €86.50 +5.68%
08/10/26 €81.85 -4.04%
07/10/26 €85.30 +0.29%
06/10/26 €85.05 -2.30%
05/10/26 €87.05 +1.34%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
86.59EUR
Average target price
103.71EUR
Spread / Average Target
+19.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE